To Determine The Effect Of Tablet Mifepristone In Induction Of Labour In Term Pregnancy In Indian Population

Abstract

Induction of labor is a critical procedure in obstetrics, performed when the continuation of pregnancy poses risks to the mother or fetus. Mifepristone, a progesterone receptor antagonist, has gained attention as an effective pharmacological agent for labor induction due to its ability to promote cervical ripening and enhance uterine sensitivity to prostaglandins. This study aims to evaluate the efficacy and safety of Mifepristone in term pregnancies among Indian women and compare its outcomes with a placebo.

A total of 85 pregnant women at term (37–42 weeks gestation) participated in this prospective randomized study. The participants were divided into two groups: those receiving Mifepristone (200 mg) and those receiving a placebo. The progression of labor was assessed through changes in the Bishop Score over 24 and 48 hours, the interval to delivery, the mode of delivery, and the need for additional prostaglandin (PGE2) gel. Data analysis was conducted to identify statistically significant differences between the groups.

The results revealed that Mifepristone significantly improved cervical ripening, as indicated by higher Bishop Scores at 24 and 48 hours compared to the placebo group. Women in the Mifepristone group experienced shorter delivery intervals and higher rates of vaginal delivery. Additionally, the need for cesarean section and supplementary PGE2 gel was notably reduced in this group. The safety profile of Mifepristone was favorable, with minimal and comparable adverse effects observed in both groups. This study demonstrates that Mifepristone is a safe and effective agent for inducing labor in term pregnancies among Indian women. It not only enhances cervical ripening and shortens delivery intervals but also increases the likelihood of vaginal delivery with reduced dependence on additional interventions. These findings highlight the potential of Mifepristone to serve as a valuable alternative to conventional induction methods, particularly in resource-limited settings where accessibility to advanced obstetric care may be constrained. Further large-scale studies are warranted to confirm these results and support the broader integration of Mifepristone into clinical practice.